Cytori Therapeutics, Inc. Reports First Quarter 2013 Business and Financial Results

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Cytori Therapeutics (NASDAQ: CYTX) today reports its first quarter 2013 financial results and provides updates on clinical development and commercialization activities.

For the first quarter of 2013, Cytori achieved $3.8 million in total revenue including $1.9 million in combined product and government contract revenue. Cytori reiterates guidance for the year of $15 million of product and contract revenue.

Help employers find you! Check out all the jobs and post your resume.

Back to news